KLP Kapitalforvaltning
MLYS icon

KLP Kapitalforvaltning’s Mineralys Therapeutics MLYS Stock Holding History

KLP Kapitalforvaltning’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$317K Hold
12,600
– – ﹤0.01% 1677
2026
Q2 		$340K Buy
12,600
+2,200
+21% +$60.4K ﹤0.01% 1677
2026
Q1 		$282K Buy
10,400
+800
+8% +$23.5K ﹤0.01% 1685
2025
Q4 		$348K Buy
9,600
+2,900
+43% +$116K ﹤0.01% 1589
2025
Q3 		$254K Hold
6,700
– – ﹤0.01% 1721
2025
Q2 		$90.7K Buy
+6,700
New +$97.1K ﹤0.01% 2070

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

KLP Kapitalforvaltning's MLYS Position: Q3 2026 in Review

KLP Kapitalforvaltning held its Mineralys Therapeutics (MLYS) position steady in Q3 2026 at 12,600 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

KLP Kapitalforvaltning first reported a position in MLYS in Q2 2025 and has held it in 6 quarters since. The position peaked at $348K in Q4 2025. 146 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • KLP Kapitalforvaltning held 12,600 shares of Mineralys Therapeutics worth $317K as of Q3 2026.
  • KLP Kapitalforvaltning left its Mineralys Therapeutics share count unchanged in Q3 2026.
  • Mineralys Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q3 2026, its #1677 holding.
  • KLP Kapitalforvaltning first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • KLP Kapitalforvaltning's Mineralys Therapeutics position peaked at $348K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2026, filed 10 Nov 2026.